Abstract
The American Society of Regional Anesthesiologists and Pain Medicine (ASRA) recently published specific recommendations to reduce the risk of bleeding and neurological injury in patients on anticoagulant and antiplatelet medications. These guidelines stratify interventional spine and pain procedures according to potential bleeding risk as low-, intermediate-, and high-risk procedures. Recommendations were evidence-based when available and pharmacology-driven otherwise. Although ASRA guidelines provide sound recommendations, a case-by-case approach must be taken to balance between bleeding and thromboembolism risk to safely manage pain interventions in patients on antiplatelet/anticoagulant therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Tryba M. Epidural regional anesthesia and low molecular heparin: pro (German). Anasth Intesivmed Notfallmed Schmerzther. 1993;28(3):179–81.
Deer T, Narouze S, Provenzano D, Pope J, Falowski S, Russo M, et al. The Neurostimulation Appropriateness Consensus Committee (NACC): recommendations on bleeding and coagulation management in neurostimulation devices. Neuromodulation. 2017;20:51–62.
Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Vasc Endovasc Surg. 1985;72(6):1177–84.
Gresele P, Momi S, Falcinelli E. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol. 2011;72(4):634–46.
Wallentin L. P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J. 2009;30(16):1964–77.
Verhoef T, Redekop W, Daly A, van Schie R, de Boer A, Maitland-van der Zee A. Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. Br J Pharmacol. 2014;77(4):626–41.
King C, Holley A, Jackson J, Shorr A, Moores L. Twice versus three times daily heparin dosing for thromboembolism prophylaxis in the general population: a metaanalysis. Chest. 2007;131(2):507–16.
Hirsch J, Warkentin T, Shaughnessy S, Anand S, Halperin J, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(1 Suppl):64S–94S.
Tripodi A. The laboratory and the direct oral anticoagulants. Blood. 2013;121(20):4032–5.
EINSTEIN Investigators, Bauersachs R, Berkowitz S, Brenner B, Buller H, Decousus H, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–510.
Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd R, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013;76(5):776–86.
Dasgupta H, Blankenship J, Wood G, Frey C, Demko S, Menapace F. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors. A pooled analysis. Am Heart J. 2000;140(21):206–11.
Jeong B, Kim S, Kim S, Kim J, Shin I, Yoon J. Use of serotonergic antidepressants and bleeding risk in patients undergoing surgery. Psychosomatics. 2014;55(3):213–20.
Chan K, Lo A, Yeung J, Woo K. The effects of Danshen (Salvia miltiorrhiza) on warfarin pharmacodynamics and pharmacokinetics of warfarin enantiomers in rats. J Pharm Pharmacol. 1995;47(5):402–6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Noori, S.A., Mehta, N. (2019). Anticoagulation. In: Abd-Elsayed, A. (eds) Pain. Springer, Cham. https://doi.org/10.1007/978-3-319-99124-5_97
Download citation
DOI: https://doi.org/10.1007/978-3-319-99124-5_97
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-99123-8
Online ISBN: 978-3-319-99124-5
eBook Packages: MedicineMedicine (R0)